Corona Remedies Limited has received Eurasian Economic Union – Good Manufacturing Practices (EAEU–GMP) certification, marking a major milestone in its international expansion strategy.
The accreditation enables Corona to enter five EAEU member countries—Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan—under a B2B business model.
EAEU–GMP certification provides access to a pharmaceutical market valued at approximately USD 25 billion. It also establishes a clear regulatory pathway for Corona to build long-term partnerships across the Eurasian region.
The certification strengthens Corona’s expansion plans across its four key therapeutic pillars:
These segments align with high unmet needs and strong demand across EAEU markets.
“This recognition opens new avenues for Corona Remedies to contribute meaningfully to healthcare systems across the Eurasian region,” said Nirav K. Mehta, CEO and Managing Director, Corona Remedies Limited. “It reflects our belief that quality healthcare should not be bound by geography. We see this as a critical step toward becoming a trusted international partner in pharmaceutical innovation.”
He added that Corona remains committed to delivering sustainable, scalable, and quality-driven solutions, guided by care, trust, and community well-being.
Corona is among the few pharmaceutical manufacturers in Gujarat to receive EAEU–GMP certification. The achievement highlights:
The company continues to operate under its guiding principle: “One World, One Quality.”
Corona Remedies Limited is a domestic, branded pharmaceutical formulation company focused on:
The company is the fastest-growing firm among the top 30 companies in the Indian Pharmaceutical Market, based on domestic sales.